Effect of an angiotensin receptor antagonist on cerebral blood flow, cerebral perfusion pressure, and systemic and peripheral haemodynamics in patients with recent stroke. - Telmisartan in Acute Stroke
- Conditions
- Patients who have hypertension in the context of recent stroke.MedDRA version: 8.1 Level: LLT Classification code 10015488 Term: Essential hypertension
- Registration Number
- EUCTR2006-005082-19-GB
- Lead Sponsor
- Research Innovation Services, University of Nottingham
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 34
•Patients must be 18 years of age or over
•Onset date of stroke is less than 5 days.
•Systolic BP >140mmHg.
•Anterior circulation stroke
•Persisting stroke symptoms at time of enrolment or visible corresponding stroke lesion on CT
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
•Less than 18 years of age
•Normotension or hypotension (systolic less than 140mmHg)
•Onset date more than 5 days
•Coma (Scandinavian Stroke Scale (SSS) <4)
•Patients who are of childbearing potential, pregnant or breastfeeding
•Known bilateral renal artery stenosis (or unilateral in a single kidney)
•GFR < 40
•TIA (defined by symptoms resolved in 24 hours with a normal CT scan)
•Posterior circulation stroke
•Dysphagia with no enteral access
•Chest infection requiring continuous oxygen therapy
•COPD requiring regular inhalers/nebulisers (mild COPD requiring PRN bronchodilators permitted)
•Known hypersensitivity to telmisartan or angiotensin receptor blockers
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method